Posted by Michael Wonder on 24 Jul 2020
Adaptimmune granted access to PRIority MEdicines (PRIME) regulatory support by the European Medicines Agency for ADP-A2M4 for the treatment of synovial sarcoma
23 July 2020 - Adaptimmune Therapeutics today announced that the EMA has granted access to the PRIME initiative to the Company for ADP-A2M4 for the treatment of synovial sarcoma.
PRIME access provides enhanced scientific and regulatory support by the EMA to developers of medicines with the potential to significantly address unmet medical needs.
Access to the PRIME initiative for ADP-A2M4 was granted based on clinical data from the Phase 1 trial demonstrating compelling efficacy and early promising durability, with tolerable safety in patients with synovial sarcoma.
